JOP20210265A1 - الأجسام المضادة لبيروغلوتامات أميلويد بيتا واستخداماتها - Google Patents
الأجسام المضادة لبيروغلوتامات أميلويد بيتا واستخداماتهاInfo
- Publication number
- JOP20210265A1 JOP20210265A1 JOP/2021/0265A JOP20210265A JOP20210265A1 JO P20210265 A1 JOP20210265 A1 JO P20210265A1 JO P20210265 A JOP20210265 A JO P20210265A JO P20210265 A1 JOP20210265 A1 JO P20210265A1
- Authority
- JO
- Jordan
- Prior art keywords
- antibodies
- antigen binding
- binding fragments
- amyloid
- pyroglutamate
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
يوفر الاختراع أجسامًا مضادة أو أجزاء منها رابطًة للمستضد - ترتبط بالبيروغلوتامات في الثمالة الثالثة (3pE A?) وطرقًا لتحضيره واستخدامه، متضمنًا ذلك استخدام التركيبات والإعطاء والأدوات. ويعد الجسم المضاد - أو الجزء منه الرابط للمستضد - والطرق التي تم الكشف عنها مفيدة لتشخيص داء ألزهايمر أو الأمراض المرتبطة بأميلويد بيتا وتشخيصها وعلاجها.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962823785P | 2019-03-26 | 2019-03-26 | |
PCT/EP2020/058395 WO2020193644A1 (en) | 2019-03-26 | 2020-03-25 | ANTIBODIES TO PYROGLUTAMATE AMYLOID-ß AND USES THEREOF |
Publications (1)
Publication Number | Publication Date |
---|---|
JOP20210265A1 true JOP20210265A1 (ar) | 2023-01-30 |
Family
ID=70008544
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JOP/2021/0265A JOP20210265A1 (ar) | 2019-03-26 | 2020-03-25 | الأجسام المضادة لبيروغلوتامات أميلويد بيتا واستخداماتها |
Country Status (21)
Country | Link |
---|---|
US (3) | US11236155B2 (ar) |
EP (1) | EP3946603A1 (ar) |
JP (1) | JP2022526528A (ar) |
KR (1) | KR20210143858A (ar) |
CN (1) | CN113891746A (ar) |
AU (1) | AU2020245031A1 (ar) |
BR (1) | BR112021019107A2 (ar) |
CA (1) | CA3134785A1 (ar) |
CL (2) | CL2021002473A1 (ar) |
CO (1) | CO2021014028A2 (ar) |
CR (1) | CR20210492A (ar) |
DO (1) | DOP2021000199A (ar) |
EA (1) | EA202192606A1 (ar) |
EC (1) | ECSP21079184A (ar) |
IL (1) | IL286634A (ar) |
JO (1) | JOP20210265A1 (ar) |
MA (1) | MA55491A (ar) |
MX (1) | MX2021011715A (ar) |
PE (1) | PE20212266A1 (ar) |
SG (1) | SG11202110504XA (ar) |
WO (1) | WO2020193644A1 (ar) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW202216760A (zh) | 2020-07-23 | 2022-05-01 | 愛爾蘭商歐薩爾普羅席納有限公司 | 抗類澱粉β (ABETA)抗體 |
EP4259657A1 (en) * | 2021-10-28 | 2023-10-18 | Abbvie Inc. | Anti-amyloid beta antibodies and methods of using the same |
TW202345899A (zh) * | 2022-03-11 | 2023-12-01 | 比利時商健生藥品公司 | 多特異性抗體及其用途(三) |
TW202346355A (zh) * | 2022-03-11 | 2023-12-01 | 比利時商健生藥品公司 | 多特異性抗體及其用途(二) |
WO2023170291A1 (en) * | 2022-03-11 | 2023-09-14 | Janssen Pharmaceutica Nv | Multispecific antibodies and uses thereof |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4166452A (en) | 1976-05-03 | 1979-09-04 | Generales Constantine D J Jr | Apparatus for testing human responses to stimuli |
US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
US5642870A (en) | 1992-08-05 | 1997-07-01 | Sargis; Ike | Switch stand |
US5761894A (en) | 1996-09-25 | 1998-06-09 | Magic Circle Corporation | Grass striping attachment for lawn mowers |
US9907485B2 (en) | 2004-10-15 | 2018-03-06 | Brainlab Ag | Targeted immunization and plaque destruction against Alzheimer's disease |
WO2006066049A2 (en) * | 2004-12-15 | 2006-06-22 | Neuralab Limited | Humanized antibodies that recognize beta amyloid peptide |
CN117903302A (zh) | 2005-11-30 | 2024-04-19 | Abbvie 公司 | 抗-Aβ球聚体抗体,其相关产品,生产所述抗体的方法,所述抗体的应用以及使用方法 |
IL199534A (en) | 2007-01-05 | 2013-01-31 | Univ Zuerich | An isolated human antibody capable of detecting a neoepitope in a disease-related protein, a polynucleotide encoding an antibody, a vector containing the polynucleotide, a host cell containing the polynucleotide or vector, a preparation containing the antibody and related methods and uses. |
US8613923B2 (en) | 2007-06-12 | 2013-12-24 | Ac Immune S.A. | Monoclonal antibody |
CA2730073A1 (en) | 2008-07-09 | 2010-01-14 | University Of Zurich | Method of promoting neurogenesis |
MX2011000875A (es) | 2008-07-21 | 2011-04-05 | Probiodrug Ag | Ensayo de anticuerpo de diagnostico. |
CN102574915B (zh) | 2009-08-06 | 2014-10-22 | 伊缪纳斯制药株式会社 | 特异性结合Aβ寡聚体的抗体及其用途 |
PE20130214A1 (es) * | 2010-02-23 | 2013-03-11 | Genentech Inc | Composiciones y metodos para el diagnostico y tratamiento de tumores |
US8795664B2 (en) * | 2010-06-04 | 2014-08-05 | Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin | Monoclonal antibodies targeting amyloid beta oligomers |
EP3042917B1 (en) * | 2010-08-12 | 2018-02-21 | Eli Lilly and Company | Anti-n3pglu amyloid beta peptide antibodies and uses thereof |
WO2012021475A2 (en) | 2010-08-12 | 2012-02-16 | Eli Lilly And Company | ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF |
EP2511296A1 (en) | 2011-04-12 | 2012-10-17 | Araclón Biotech, S. L. | Antibody, kit and method for determination of amyloid peptides |
ITRM20120383A1 (it) | 2012-03-20 | 2013-09-21 | Uni Degli Studi Di Milano B Icocca | Metodo e kit per la rivelazione di anticorpi. |
WO2015175769A1 (en) | 2014-05-15 | 2015-11-19 | Biogen Ma Inc. | Methods for the detection of amyloid beta oligomers in biological samples |
WO2015191825A1 (en) | 2014-06-13 | 2015-12-17 | Biogen Ma Inc. | Methods for the detection and measurement of amyloid beta in biological samples |
NZ728425A (en) * | 2014-08-07 | 2022-05-27 | Novartis Ag | Angiopoietin-like 4 antibodies and methods of use |
EP3234611A1 (en) | 2014-12-19 | 2017-10-25 | Probiodrug AG | Novel method for the detection of pglu-abeta peptides |
JP7002811B2 (ja) | 2015-07-16 | 2022-03-04 | ビボリョン セラピューティクス エヌブイ | 抗ピログルタミン酸化アミロイドβヒト化抗体 |
JOP20170004B1 (ar) | 2016-01-15 | 2022-09-15 | Lilly Co Eli | الأجسام المضادة لببتيد بيتا النشوي مضاد N3pGlu واستخداماته |
TW201740954A (zh) | 2016-03-16 | 2017-12-01 | 美國禮來大藥廠 | 組合療法 |
EP3249388A1 (en) | 2016-05-23 | 2017-11-29 | Raman Health Technologies, S.L | Method for diagnosing alzheimer´s disease |
KR20230165883A (ko) | 2016-06-07 | 2023-12-05 | 바이오겐 인터내셔널 뉴로사이언스 게엠베하 | 알츠하이머병의 치료 방법 |
WO2018031361A2 (en) | 2016-08-09 | 2018-02-15 | Eli Lilly And Company | Combination therapy |
AR110470A1 (es) | 2016-10-21 | 2019-04-03 | Lilly Co Eli | Terapia de combinación para tratar la enfermedad de alzheimer |
TW201827467A (zh) * | 2016-11-03 | 2018-08-01 | 比利時商健生藥品公司 | 焦穀胺酸類澱粉蛋白-β之抗體及其用途 |
JOP20190247A1 (ar) | 2017-04-20 | 2019-10-20 | Lilly Co Eli | أجسام بيتا ببتيد النشوانية المضادة لـ N3pGlu واستخداماتها |
KR20200030029A (ko) * | 2017-05-02 | 2020-03-19 | 프로테나 바이오사이언시즈 리미티드 | 타우 인식 항체 |
CA3073066A1 (en) | 2017-08-22 | 2019-02-28 | Biogen Ma Inc. | Pharmaceutical compositions containing anti-beta amyloid antibodies |
CN113164777A (zh) * | 2018-09-27 | 2021-07-23 | 马伦戈治疗公司 | Csf1r/ccr2多特异性抗体 |
-
2020
- 2020-03-25 PE PE2021001598A patent/PE20212266A1/es unknown
- 2020-03-25 CR CR20210492A patent/CR20210492A/es unknown
- 2020-03-25 JO JOP/2021/0265A patent/JOP20210265A1/ar unknown
- 2020-03-25 JP JP2021557190A patent/JP2022526528A/ja active Pending
- 2020-03-25 CN CN202080039618.2A patent/CN113891746A/zh active Pending
- 2020-03-25 KR KR1020217034312A patent/KR20210143858A/ko active Search and Examination
- 2020-03-25 MX MX2021011715A patent/MX2021011715A/es unknown
- 2020-03-25 EP EP20714579.8A patent/EP3946603A1/en active Pending
- 2020-03-25 AU AU2020245031A patent/AU2020245031A1/en active Pending
- 2020-03-25 WO PCT/EP2020/058395 patent/WO2020193644A1/en active Application Filing
- 2020-03-25 US US16/829,029 patent/US11236155B2/en active Active
- 2020-03-25 US US17/598,280 patent/US20220177560A1/en active Pending
- 2020-03-25 BR BR112021019107A patent/BR112021019107A2/pt unknown
- 2020-03-25 EA EA202192606A patent/EA202192606A1/ru unknown
- 2020-03-25 MA MA055491A patent/MA55491A/fr unknown
- 2020-03-25 CA CA3134785A patent/CA3134785A1/en active Pending
- 2020-03-25 SG SG11202110504XA patent/SG11202110504XA/en unknown
-
2021
- 2021-09-23 CL CL2021002473A patent/CL2021002473A1/es unknown
- 2021-09-23 IL IL286634A patent/IL286634A/en unknown
- 2021-09-23 DO DO2021000199A patent/DOP2021000199A/es unknown
- 2021-10-20 CO CONC2021/0014028A patent/CO2021014028A2/es unknown
- 2021-10-26 EC ECSENADI202179184A patent/ECSP21079184A/es unknown
- 2021-12-17 US US17/554,461 patent/US20220106387A1/en active Pending
-
2022
- 2022-09-29 CL CL2022002670A patent/CL2022002670A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
KR20210143858A (ko) | 2021-11-29 |
BR112021019107A2 (pt) | 2021-11-30 |
CN113891746A (zh) | 2022-01-04 |
CA3134785A1 (en) | 2020-10-01 |
EA202192606A1 (ru) | 2022-01-24 |
CL2022002670A1 (es) | 2023-03-31 |
SG11202110504XA (en) | 2021-10-28 |
CO2021014028A2 (es) | 2021-10-29 |
AU2020245031A1 (en) | 2021-10-21 |
EP3946603A1 (en) | 2022-02-09 |
CR20210492A (es) | 2021-11-19 |
MX2021011715A (es) | 2021-12-10 |
PE20212266A1 (es) | 2021-11-30 |
JP2022526528A (ja) | 2022-05-25 |
US20200308261A1 (en) | 2020-10-01 |
MA55491A (fr) | 2022-02-09 |
US20220106387A1 (en) | 2022-04-07 |
ECSP21079184A (es) | 2021-11-30 |
DOP2021000199A (es) | 2022-07-15 |
CL2021002473A1 (es) | 2022-04-22 |
IL286634A (en) | 2021-10-31 |
US11236155B2 (en) | 2022-02-01 |
WO2020193644A1 (en) | 2020-10-01 |
US20220177560A1 (en) | 2022-06-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JOP20210265A1 (ar) | الأجسام المضادة لبيروغلوتامات أميلويد بيتا واستخداماتها | |
ZA202005259B (en) | Anti-ctla4 antibodies and methods of making and using the same | |
UA109633C2 (uk) | Антитіло людини проти тканинного фактора | |
MY194997A (en) | Anti-ccr7 antibody drug conjugates | |
JOP20180117B1 (ar) | أجسام مضادة انتقائية لـ tau فائق المعالجة بفوسفوريلات وطرق لاستخدامها | |
WO2006084075A3 (en) | Adam-9 modulators | |
WO2008066691A3 (en) | Tes7 and antibodies that bind thereto | |
MA37761A1 (fr) | Protéines de liaison à un antigène antagoniste d'un double récepteur et leurs utilisations | |
WO2019186276A8 (en) | Antibody-based methods of detecting and treating alzheimer's disease | |
AR069290A1 (es) | Anticuerpos monoclonales que se unen al hgm -csf (factor estimulante de la colonia de granulocitos-macrofagos) y las composiciones medicas que los comprenden | |
BRPI0414513A (pt) | kid3 e anticorpos de kid3 que se ligam a ele | |
WO2006084092A3 (en) | Antibodies to oncostatin m receptor | |
MX2021004808A (es) | Anticuerpos contra la epcam, anticuerpos activables e inmunoconjugados y usos de estos. | |
WO2006084078A3 (en) | Jam-3 and antibodies that bind thereto | |
WO2006083852A3 (en) | Luca2 and antibodies that bind thereto | |
WO2006076584A3 (en) | Kid31 and antibodies that bind thereto | |
EA202192090A1 (ru) | Антигенсвязывающие белки против гамма-цепи рецептора il2 | |
WO2019234241A8 (en) | ANTI-oxMIF/ANTI-CD3 ANTIBODY FOR CANCER TREATMENT | |
PH12020552006A1 (en) | Antibodies specific for cd3 and uses thereof | |
MX2021006362A (es) | Anticuerpos de dominio simple contra cll-1. | |
EA201492162A1 (ru) | Антитела к трансглютаминазе 2 | |
MX2022004194A (es) | Anticuerpos contra el receptor de virus de la polio (pvr) y usos de los mismos. | |
EA202100199A1 (ru) | Моноклональные антитела, специфически связывающиеся с trbv-9 человека | |
MA44917B1 (fr) | Anticorps ou son fragment de liaison d’antigènes apte a se lier au récepteur d'interleukine-6 de l'humain. | |
MX2021007593A (es) | Anticuerpos anti-pmel17 y conjugados de los mismos. |